发明名称 |
Modified/chimeric superantigens and their use |
摘要 |
A novel conjugate comprises a target seeking moiety and a modified wild type superantigen; the modified superantigen retains its ability to activate a subset of T cells, even though 1 or more wild-type amino acid residues in at least 1 region which functions in determining binding to T cell receptor (TCR)and activation of a subset of T cells has/have been replaced. Also claimed is the use of a modified superantigen as above, optionally as part of a conjugate with a target seeking moiety, for activating the immune system to treat a mammalian disease. Also new is a pharmaceutical composition comprising a modified antibody (preferably a Fab fragment fused to a peptide moiety providing activation of T cells in V~b specific manner) in which cysteines providing for interchain cysteine linkages in the native antibody have been replaced (preferably by serine residues) to prohibit cystine formation. |
申请公布号 |
AU707827(B2) |
申请公布日期 |
1999.07.22 |
申请号 |
AU19970025251 |
申请日期 |
1997.03.26 |
申请人 |
PHARMACIA & UPJOHN AB |
发明人 |
PER ANTONSSON;JOHAN HANSSON;PER BJORK;MIKAEL DOHLSTEN;TERJE KALLAND;LARS ABRAHMSEN;GORAN FORSBERG |
分类号 |
A61K39/085;A61K38/00;A61K39/09;A61K39/12;A61K39/385;A61K39/395;A61K47/48;A61P31/12;A61P33/00;A61P35/00;A61P37/02;C07K14/31;C07K16/30;C07K19/00;(IPC1-7):C07K19/00 |
主分类号 |
A61K39/085 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|